JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

Going into 2025, the PGM remains strong, with the potential for other regions to start closing the gap with the United States ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

Investment opportunities in frontier markets debt have increased in recent years as a result of structural improvements, ...

Palantir Technologies (PLTR – Research Report) received a Hold rating and price target from William Blair analyst Louie DiPalma today. The ...

Equities researchers at William Blair increased their Q1 2025 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a report released on Monday, March 3rd. William Blair analyst M.

William Blair upgraded Zealand Pharma (ZLDPF) to Outperform from Market Perform without a price target The firm sees the recent share pullback ...

Fintel reports that on March 7, 2025, William Blair upgraded their outlook for American Public Education (NasdaqGS:APEI) from ...

Equities research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for GitLab in a research ...

William Blair restated their outperform rating on shares of AeroVironment (NASDAQ:AVAV – Free Report) in a research report ...

Investment analysts at William Blair issued their Q1 2025 earnings per share (EPS) estimates for shares of Biodesix in a research note issued on Tuesday, March 4th. William Blair analyst A. Brackmann ...

Fintel reports that on March 5, 2025, William Blair upgraded their outlook for Palantir Technologies (NasdaqGS:PLTR) from ...